Garland Surgical (Cohort 8.0) shortlisted for 2025 Santander X UK & BioSeed OBN Awards.

---

Accelerate Cohort 8.0 alumni & Entrepreneurs in Residence, Garland Surgical have been shortlisted for both the 2025 Santander X UK & BioSeed OBN Awards.

---

We're incredibly pleased to share that BetaDen Accelerate Cohort 8.0 alumni and current Entrepreneurs in Residence, Garland Surgical have been shortlisted for the Santander X UK Awards 2025 and announced as finalists in two categories at the 2025 BioSeed OBN Awards.

Garland Surgical, who are developing the exciting & innovative Malta Hip, a longer-lasting hip replacement - seeking to make the procedure a once-in-a-lifetime operation, fought off 1,200 applicants to receive their Santander nomination alongside the remarkable achievement of being selected as finalists in both the Best Early Stage Medtech Company Award & The BioSeed One to Watch Award categories at the OBN Awards.

We would like to offer a massive congratulations to Garland on this brilliant recognition of our pioneering work and we wish them the best in both prestigious competitions.

To read the full LinkedIn announcement from Garland on their Satander X nomination, use the link here.

To read the full LinkedIn announcement on their selection as OBN Awards finalists, use the link here.